HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

2',6'- dimethyltyrosyl- 1,2,3,4- tetrahydroisoquinoline- 3- carboxylic acid (1H- benzimidazol- 2- yl)(carboxymethyl)methylamide

structure in first source
Also Known As:
Dmt-Tic-NH-CH(CH2-COOH)-Bid; UFP 512; UFP-512; UFP512
Networked: 13 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Xia, Ying: 9 articles (01/2022 - 01/2012)
2. Balboni, Gianfranco: 5 articles (01/2022 - 07/2013)
3. Yang, Yilin: 4 articles (01/2022 - 01/2012)
4. Zhi, Feng: 4 articles (01/2022 - 01/2012)
5. Chao, Dongman: 4 articles (08/2014 - 01/2012)
6. Xu, Yuan: 3 articles (01/2022 - 08/2016)
7. He, Xiaozhou: 3 articles (01/2019 - 01/2012)
8. Peng, Ya: 2 articles (01/2022 - 01/2019)
9. Shao, Naiyuan: 2 articles (01/2019 - 08/2016)
10. Wang, Rong: 2 articles (08/2016 - 01/2012)

Related Diseases

1. Neuroblastoma
2. Hypoxia (Hypoxemia)
01/01/2019 - "The results showed that endogenous DOR expression remained unchanged under hypoxia, while DOR activation with UFP-512 (a specific DOR agonist) reversed the hypoxia-induced up-regulation of ERK1/2 and p38 phosphorylation. "
01/01/2019 - "Using highly differentiated rat PC12 cells exposed to either severe hypoxia (0.5-1% O2) for 24-48 h or varying concentrations of MPP+, we found that both hypoxic and MPP+ stress reduced the level of PINK1 expression, while incubation with the specific DOR agonist UFP-512 reversed this reduction and protected the cells from hypoxia and/or MPP+-induced injury. "
08/01/2014 - "We found that hypoxia reduced cell viability in both astrocytes and PC-12 cells, and DOR activation with UFP-512 (5 μM) effectively protected both the cells against hypoxic insult. "
07/31/2013 - "The results showed that: (1) 1-day hypoxia had no appreciable effect on BDNF expression, while 3- and 10-day hypoxia progressively decreased BDNF expression, resulting in 37.3% reduction (p < 0.05) after 10-day exposure; (2) DOR activation with UFP-512 (1 mg/kg, i.p., daily) partially reversed the hypoxia-induced reduction of BDNF expression in the 3- or 10-day exposed cortex; (3) DOR activation partially reversed the hypoxia-induced reduction in functional TrkB (140-kDa) and attenuated hypoxia-induced increase in truncated TrkB (90-kDa) in the 3- or 10-day hypoxic cortex; and (4) prolonged hypoxia (10 days) significantly increased TNF-α level and decreased CD11b expression in the cortex, which was completely reversed following DOR activation; and (5) there was no significant change in pCREB and pATF-1 levels in the hypoxic cortex. "
01/01/2012 - "To determine if the miRNAs expressed in the cortex mediated DOR neuroprotection, we examined 19 miRNAs that were previously identified as hypoxia- and DOR-regulated miRNAs in the kidney, in the rat cortex treated with UFP-512, a potent and specific DOR agonist under hypoxic condition. "
3. Neuralgia (Stump Neuralgia)
4. Chronic Pain
5. Parkinsonian Disorders (Parkinsonism)

Related Drugs and Biologics

1. Proteins (Proteins, Gene)
2. 2',6'- dimethyltyrosyl- 1,2,3,4- tetrahydroisoquinoline- 3- carboxylic acid (1H- benzimidazol- 2- yl)(carboxymethyl)methylamide
3. naltrindole
4. Caspase 3 (Caspase-3)
5. Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
6. Synucleins
7. Heme Oxygenase-1
8. Proto-Oncogene Proteins c-akt (Protein Kinase B)
9. Mitogen-Activated Protein Kinase 3
10. JNK Mitogen-Activated Protein Kinases